Glaxosmithkline Plc (ADR) (NYSE:GSK) And Sanford Burnham’s Teamwork Lead To The Launch …

The launch of a new Translational Neuroscience centre dubbed ‘SBP-GSK centre’ is as a result of combined efforts between London’s GlaxoSmithKline plc (ADR) (NYSE:GSK) and Sanford Burnham Prebys Medical Discovery Institute. The centre intends to bring together staffs from Sanford Burnham and GSK who will take over the investigation of factors manipulating the brain function which eventually reverses or slows down neurodegeneration. The two are somewhat interrelated in that SBP’s CEO Perry Nisen was once a senior VP of science and innovation at GSK. In fact, Nisen’s shift of positions initiated the Institute’s new strategy to become the “partner of choice” for drugmakers. Besides, it has been able to obtain research deals with Eli Lilly and Co (NYSE:LLY) and Daiichi Sankyo as it gets deeper into drug discovery. There are…


Link to Full Article: Glaxosmithkline Plc (ADR) (NYSE:GSK) And Sanford Burnham’s Teamwork Lead To The Launch …

Pin It on Pinterest

Share This